Perrigo Company PLC (PRGO) Q1 2026 Earnings Call Transcript

Why It Matters

The restructuring and cost‑saving measures aim to offset market softness while positioning Perrigo for sustainable growth, directly impacting investors and the broader consumer‑health sector.

Key Takeaways

• All‑In EPS rose 7% to $2.75, meeting guidance.
• CORE Perrigo EPS increased 14% to $2.52 year‑over‑year.
• Infant formula sales fell 25% Q4, 10% full year.
• Up to $350 M additional goodwill impairment possible Q1 2026.
• 7% workforce cut targets $80‑100 M annual pretax savings.

Pulse Analysis

Perrigo’s latest earnings call underscored the lingering softness in the over‑the‑counter (OTC) market, which has pressured organic net sales across its core segments. Despite a 2% rise in All‑In operating income, the company’s fourth‑quarter CORE organic sales slipped 2%, reflecting reduced consumer demand and inventory adjustments by retailers. Nevertheless, disciplined cost management and the $320 million benefit from Project Energize helped lift EPS to $2.75, aligning with the company’s revised outlook and signaling resilience amid a challenging macro environment.

To counteract the revenue headwinds, Perrigo is accelerating a multi‑year transformation plan that includes a 7% reduction in its global workforce and targeted cost‑saving initiatives projected to generate $80‑100 million of annual pretax savings. The firm also disclosed a potential $350 million non‑cash goodwill impairment in the first quarter of 2026, following a $1.3 billion charge for 2025 underperformance. Strategic divestitures, notably the sale of Dermacosmetics, are earmarked to reduce debt and sharpen the portfolio toward high‑margin self‑care and specialty‑care products. These actions aim to improve leverage, which stood at 4x at year‑end, and preserve cash flow as the company navigates the transition.

Looking ahead, Perrigo will adopt new segment reporting—Self‑care, Specialty Care, and Infant Formula—to enhance transparency and align with its operating model. The innovation pipeline, now valued three times higher than the prior year, is expected to drive the majority of growth in the second half of 2026. Combined with anticipated share‑gain momentum and geographic expansion, the company projects CORE EPS between $2.25 and $2.55, despite a $0.60 EPS drag from plant under‑absorption. Investors will watch how these strategic levers translate into margin recovery and long‑term value creation.